Association between genome-wide epigenetic and genetic alterations in breast cancer tissue and response to HER2-targeted therapies in HER2-positive breast cancer patients: new findings and a systematic review

Abstract

Recent evidence suggests that genetic and epigenetic mechanisms might be associated with acquired resistance to cancer therapies. The aim of this study was to assess the association of genome-wide genetic and epigenetic alterations with the response to anti-HER2 agents in HER2-positive breast cancer patients. PubMed was screened for articles published until March 2021 on observational studies investigating the association of genome-wide genetic and epigenetic alterations, measured in breast cancer tissues or blood, with the response to targeted treatment in HER2-positive breast cancer patients. Sixteen studies were included in the review along with ours, in which we compared the genome-wide DNA methylation pattern in breast tumor tissues of patients who acquired resistance to treatment (case group, n = 6) to that of patients who did not develop resistance (control group, n = 6). Among genes identified as differentially methylated between the breast cancer tissue of cases and controls, one of them, PRKACA, was also reported as differentially expressed in two studies included in the review. Although included studies were heterogeneous in terms of methodology and study population, our review suggests that genes of the PI3K pathway may play an important role in developing resistance to anti-HER2 agents in breast cancer patients. Genome-wide genetic and epigenetic alterations measured in breast cancer tissue or blood might be promising markers of resistance to anti-HER2 agents in HER2-positive breast cancer patients. Further studies are needed to confirm these data.

Keywords

Breast neoplasms / epigenetics / genetics / HER2 inhibitors / treatment response / biomarkers

References

[1] Yarden Y.Untangling the ErbB signalling network.Nat Rev Mol Cell Biol2001;2:127-37

[2] Carpenter G.Receptors for epidermal growth factor and other polypeptide mitogens.Annu Rev Biochem1987;56:881-914

[3] Soerjomataram I,Ribot JG,Coebergh JW.An overview of prognostic factors for long-term survivors of breast cancer.Breast Cancer Res Treat2008;107:309-30 PMCID:PMC2217620

[4] Esteva FJ,Hung MC.Molecular predictors of response to trastuzumab and lapatinib in breast cancer.Nat Rev Clin Oncol2010;7:98-107

[5] Wolff AC,Hicks DG.American Society of Clinical OncologyCollege of American PathologistsRecommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.J Clin Oncol2013;31:3997-4013

[6] Arteaga CL,Osborne CK,Puglisi F.Treatment of HER2-positive breast cancer: current status and future perspectives.Nat Rev Clin Oncol2011;9:16-32

[7] Poon KA,Beyer J.Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability.Toxicol Appl Pharmacol2013;273:298-313

[8] Balduzzi S,Guarneri V.Trastuzumab-containing regimens for metastatic breast cancer.Cochrane Database Syst Rev2014;:CD006242 PMCID:PMC6464904

[9] Moja L,Balduzzi S.Trastuzumab containing regimens for early breast cancer.Cochrane Database Syst Rev2012;:CD006243 PMCID:PMC6718210

[10] Swain SM,Kim SB.CLEOPATRA Study GroupPertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.N Engl J Med2015;372:724-34 PMCID:PMC5584549

[11] Xu ZQ,Li N.Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials.BMJ Open2017;7:e013053 PMCID:PMC5353336

[12] D’Amato V,Formisano L.Mechanisms of lapatinib resistance in HER2-driven breast cancer.Cancer Treat Rev2015;41:877-83

[13] de Melo Gagliato D, Jardim DL, Marchesi MS, Hortobagyi GN. Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer.Oncotarget2016;7:64431-46 PMCID:PMC5325455

[14] Nahta R,Hung MC,Esteva FJ.Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.Nat Clin Pract Oncol2006;3:269-80

[15] Zhang S,Li P.Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways.Nat Med2011;17:461-9 PMCID:PMC3877934

[16] Beauclair S,Fischel JL.Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity.Ann Oncol2007;18:1335-41

[17] Borley A,Morgan M.Impact of HER2 copy number in IHC2+/FISH-amplified breast cancer on outcome of adjuvant trastuzumab treatment in a large UK cancer network.Br J Cancer2014;110:2139-43 PMCID:PMC3992505

[18] Boulbes DR,Chauhan GB.HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer.Mol Oncol2015;9:586-600 PMCID:PMC4815926

[19] Furrer D,Michaud A,Lemieux J.Association of tobacco use, alcohol consumption and HER2 polymorphisms with response to trastuzumab in HER2-positive breast cancer patients.Clin Breast Cancer2018;18:e687-94

[20] Gavin PG,Kim SR.Association of polymorphisms in FCGR2A and FCGR3A with degree of trastuzumab benefit in the adjuvant treatment of ERBB2/HER2-positive breast cancer: analysis of the NSABP B-31 trial.JAMA Oncol2017;3:335-41 PMCID:PMC5344747

[21] Han X,Xu Y.Association between the HER2 Ile655Val polymorphism and response to trastuzumab in women with operable primary breast cancer.Ann Oncol2014;25:1158-64

[22] Hurvitz SA,Stern HM.Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients.Clin Cancer Res2012;18:3478-86 PMCID:PMC3821872

[23] Jackson C,Gautrey H.Clinical significance of HER-2 splice variants in breast cancer progression and drug resistance.Int J Cell Biol2013;2013:973584 PMCID:PMC3713377

[24] Musolino A,Bortesi B.Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.J Clin Oncol2008;26:1789-96

[25] Norton N,Pegram M.Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) trial N9831.Cancer Immunol Res2014;2:962-9 PMCID:PMC4215796

[26] Scaltriti M,Ocaña A.Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.J Natl Cancer Inst2007;99:628-38

[27] Tamura K,Hojo T.FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer.Ann Oncol2011;22:1302-7

[28] Toomey S,Furney SJ.The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer.Oncotarget2016;7:75518-25 PMCID:PMC5342757

[29] He DX,Gao F.Genome-wide profiles of methylation, microRNAs, and gene expression in chemoresistant breast cancer.Sci Rep2016;6:24706 PMCID:PMC4837395

[30] Klajic J,Edvardsen H.DNA methylation status of key cell-cycle regulators such as CDKNA2/p16 and CCNA1 correlates with treatment response to doxorubicin and 5-fluorouracil in locally advanced breast tumors.Clin Cancer Res2014;20:6357-66

[31] Lackner MR,Settleman J.Mechanisms of acquired resistance to targeted cancer therapies.Future Oncol2012;8:999-1014

[32] Ye XM,Bai WD.Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R.BMC Cancer2014;14:134 PMCID:PMC3974046

[33] Jin B,Robertson KD.DNA methylation: superior or subordinate in the epigenetic hierarchy?.Genes Cancer2011;2:607-17 PMCID:PMC3174260

[34] Jjingo D,Yi SV,Jordan IK.On the presence and role of human gene-body DNA methylation.Oncotarget2012;3:462-74 PMCID:PMC3380580

[35] Maunakea AK,Bilenky M.Conserved role of intragenic DNA methylation in regulating alternative promoters.Nature2010;466:253-7 PMCID:PMC3998662

[36] Wahid F,Khan T.MicroRNAs: synthesis, mechanism, function, and recent clinical trials.Biochim Biophys Acta2010;1803:1231-43

[37] Furrer D,Caron C,Provencher L.Tissue microarray is a reliable tool for the evaluation of HER2 amplification in breast cancer.Anticancer Res2016;36:4661-6

[38] Bibikova M,Tsan C.High density DNA methylation array with single CpG site resolution.Genomics2011;98:288-95

[39] Du P,Huang CC.Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis.BMC Bioinformatics2010;11:587 PMCID:PMC3012676

[40] Pidsley R,Volta M,Mill J.A data-driven approach to preprocessing Illumina 450K methylation array data.BMC Genomics2013;14:293 PMCID:PMC3769145

[41] Chen YA,Choufani S.Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray.Epigenetics2013;8:203-9 PMCID:PMC3592906

[42] Leek JT,Bravo HC.Tackling the widespread and critical impact of batch effects in high-throughput data.Nat Rev Genet2010;11:733-9 PMCID:PMC3880143

[43] Page MJ,Bossuyt PM.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.PLoS Med2021;18:e1003583 PMCID:PMC8007028

[44] Sterne JA,Reeves BC.ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions.BMJ2016;355:i4919 PMCID:PMC5062054

[45] Harris LN,Schnitt SJ.Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer.Clin Cancer Res2007;13:1198-207

[46] Khoury T,Wang D.Breast carcinoma with amplified HER2: a gene expression signature specific for trastuzumab resistance and poor prognosis.Mod Pathol2010;23:1364-78

[47] Gámez-Pozo A,Manso L.The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy.PLoS One2014;9:e109611 PMCID:PMC4203741

[48] Guarneri V,Frassoldati A.Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer.Oncologist2015;20:1001-10 PMCID:PMC4571802

[49] Triulzi T,Sandri M.Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration.Oncotarget2015;6:28173-82 PMCID:PMC4695052

[50] Merry CR,Forrest ME.Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancer.Oncotarget2016;7:53230-44 PMCID:PMC5288181

[51] Zhao B,Sun Y.Alterations in mRNA profiles of trastuzumab‑resistant Her‑2‑positive breast cancer.Mol Med Rep2018;18:139-46 PMCID:PMC6059662

[52] Sorokin M,Barbara V.Molecular pathway activation markers are associated with efficacy of trastuzumab therapy in metastatic HER2-positive breast cancer better than individual gene expression levels.Biochemistry (Mosc)2020;85:758-72

[53] Perez EA,Ballman KV.Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.J Clin Oncol2015;33:701-8 PMCID:PMC4334774

[54] Du F,Zhao ZT.A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment.Sci Rep2016;6:33825 PMCID:PMC5030658

[55] Ohzawa H,Teratani T.Usefulness of miRNA profiles for predicting pathological responses to neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer.Oncol Lett2017;13:1731-40 PMCID:PMC5403717

[56] Walsh N,O’Donovan P.Whole-exome sequencing of long-term, never relapse exceptional responders of trastuzumab-treated HER2+ metastatic breast cancer.Br J Cancer2020;123:1219-22 PMCID:PMC7553955

[57] Yang T,Zhang Y,Mao C.Serum proteomics analysis of candidate predictive biomarker panel for the diagnosis of trastuzumab-based therapy resistant breast cancer.Biomed Pharmacother2020;129:110465

[58] Lesurf R,Griffith M.Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial.Ann Oncol2017;28:1070-7 PMCID:PMC5790063

[59] Shi W,Nuciforo P.Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.Ann Oncol2019;30:1018 PMCID:PMC6594454

[60] Berthon AS,Stratakis CA.PRKACA: the catalytic subunit of protein kinase A and adrenocortical tumors.Front Cell Dev Biol2015;3:26 PMCID:PMC4438593

[61] Kordowski F,Schafmayer C.Aberrant DNA methylation of ADAMTS16 in colorectal and other epithelial cancers.BMC Cancer2018;18:796 PMCID:PMC6080380

[62] Kumar S,Ge R.Emerging roles of ADAMTSs in angiogenesis and cancer.Cancers (Basel)2012;4:1252-99 PMCID:PMC3712723

[63] Li Y,Zhang Q,Cai Z.Ubiquitin-specific protease 4 inhibits breast cancer cell growth through the upregulation of PDCD4.Int J Mol Med2016;38:803-11 PMCID:PMC4990282

[64] Moody SE,Singh S.PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling.Oncogene2015;34:2061-71 PMCID:PMC4261061

[65] Nguyen HH,Nguyen T,Yun SI.A selective inhibitor of ubiquitin-specific protease 4 suppresses colorectal cancer progression by regulating β-catenin signaling.Cell Physiol Biochem2019;53:157-71

[66] Qin N,Li L.Deubiquitinating enzyme 4 facilitates chemoresistance in glioblastoma by inhibiting P53 activity.Oncol Lett2019;17:958-64 PMCID:PMC6312926

[67] Tomasini MD,Karamafrooz A.Conformational landscape of the PRKACA-DNAJB1 chimeric kinase, the driver for fibrolamellar hepatocellular carcinoma.Sci Rep2018;8:720 PMCID:PMC5768683

[68] Tomino T,Tatsuguchi T.DOCK1 inhibition suppresses cancer cell invasion and macropinocytosis induced by self-activating Rac1^P29S mutation.Biochem Biophys Res Commun2018;497:298-304

[69] Zhang B,Yin C.Dock1 promotes the mesenchymal transition of glioma and is modulated by MiR-31.Neuropathol Appl Neurobiol2017;43:419-32

[70] Laurin M.Insights into the biological functions of Dock family guanine nucleotide exchange factors.Genes Dev2014;28:533-47 PMCID:PMC3967044

[71] Liang Y,Zhang Y.Downregulation of Dock1 and Elmo1 suppresses the migration and invasion of triple-negative breast cancer epithelial cells through the RhoA/Rac1 pathway.Oncol Lett2018;16:3481-8 PMCID:PMC6096110

[72] Kesteloot F,Leclercq I.ADAM metallopeptidase with thrombospondin type 1 motif 2 inactivation reduces the extent and stability of carbon tetrachloride-induced hepatic fibrosis in mice.Hepatology2007;46:1620-31

[73] Dubail J,Deroanne C.ADAMTS-2 functions as anti-angiogenic and anti-tumoral molecule independently of its catalytic activity.Cell Mol Life Sci2010;67:4213-32

[74] Thorolfsdottir RB,Sulem P.A missense variant in PLEC increases risk of atrial fibrillation.J Am Coll Cardiol2017;70:2157-68 PMCID:PMC5704994

[75] Paumard-Hernández B,Inglada Pérez L.Whole exome sequencing identifies PLEC, EXO5 and DNAH7 as novel susceptibility genes in testicular cancer.Int J Cancer2018;143:1954-62

[76] Reyes-Turcu FE,Wilkinson KD.Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes.Annu Rev Biochem2009;78:363-97 PMCID:PMC2734102

[77] Fumagalli D,Ignatiadis M.RNA sequencing to predict response to neoadjuvant anti-HER2 therapy: a secondary analysis of the NeoALTTO randomized clinical trial.JAMA Oncol2017;3:227-34 PMCID:PMC5374044

[78] Triulzi T,De Cecco L.Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit.Br J Cancer2018;119:1487-94 PMCID:PMC6288086

[79] Brodsky AS,Yang D.Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer.BMC Cancer2016;16:274 PMCID:PMC4835834

[80] Hendricks WPD,Halperin RF.PD-1-associated gene expression signature of neoadjuvant trastuzumab-treated tumors correlates with patient survival in HER2-positive breast cancer.Cancers (Basel)2019;11:1566 PMCID:PMC6826891

[81] Powles RL,Sotiriou C.Association of T-Cell receptor repertoire use with response to combined trastuzumab-lapatinib treatment of HER2-positive breast cancer: secondary analysis of the NeoALTTO randomized clinical trial.JAMA Oncol2018;4:e181564 PMCID:PMC6224305

[82] Varadan V,Miskimen KL.Immune signatures following single dose trastuzumab predict pathologic response to preoperativetrastuzumab and chemotherapy in HER2-positive early breast cancer.Clin Cancer Res2016;22:3249-59 PMCID:PMC5439498

[83] Ye Y,Sun Z.Upregulated WDR26 serves as a scaffold to coordinate PI3K/AKT pathway-driven breast cancer cell growth, migration, and invasion.Oncotarget2016;7:17854-69 PMCID:PMC4951255

[84] Loibl S,Guarneri V.PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.Ann Oncol2019;30:1180

[85] Takada M,Tozuka K.Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy.BMC Cancer2013;13:241 PMCID:PMC3663661

[86] Berns K,Hennessy BT.A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.Cancer Cell2007;12:395-402

[87] Zhang B,Lin N.Functional DNA methylation differences between tissues, cell types, and across individuals discovered using the M&M algorithm.Genome Res2013;23:1522-40 PMCID:PMC3759728

[88] Galanter JM,Oh SS.Differential methylation between ethnic sub-groups reflects the effect of genetic ancestry and environmental exposures.Elife2017;6:e20532 PMCID:PMC5207770

[89] Benevolenskaya EV,Ahsan H.DNA methylation and hormone receptor status in breast cancer.Clin Epigenetics2016;8:17 PMCID:PMC4754852

[90] Ciccarone F,Caiafa P.DNA methylation dynamics in aging: how far are we from understanding the mechanisms?.Mech Ageing Dev2018;174:3-17

[91] Abba MC,Sun H.Gene expression signature of estrogen receptor alpha status in breast cancer.BMC Genomics2005;6:37 PMCID:PMC555753

[92] Adkins RM,Tylavsky FA.Racial differences in gene-specific DNA methylation levels are present at birth.Birth Defects Res A Clin Mol Teratol2011;91:728-36 PMCID:PMC3429933

[93] Sempere LF,Silahtaroglu A.Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer.Cancer Res2007;67:11612-20

[94] Van Grembergen O,de Bony EJ.Portraying breast cancers with long noncoding RNAs.Sci Adv2016;2:e1600220 PMCID:PMC5010371

[95] Witte T,Gerhauser C.Pan-cancer patterns of DNA methylation.Genome Med2014;6:66 PMCID:PMC4254427

[96] Yerukala Sathipati S, Ho SY. Identifying a miRNA signature for predicting the stage of breast cancer.Sci Rep2018;8:16138 PMCID:PMC6208346

[97] Le X,Razavi P.Systematic functional characterization of resistance to pi3k inhibition in breast cancer.Cancer Discov2016;6:1134-47 PMCID:PMC5050154

[98] Rasti AR,Datko F,Aisner DL..PIK3CA6:e2100370 PMCID:PMC8984255

[99] Rimawi MF,Contreras A.Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.Breast Cancer Res Treat2018;167:731-40 PMCID:PMC5821069

[100] O’Brien NA,Chow L.Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.Mol Cancer Ther2010;9:1489-502